PBH:NYE-Prestige Brand Holdings Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 71.57

Change

-0.24 (-0.33)%

Market Cap

USD 2.60B

Volume

0.17M

Analyst Target

USD 45.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Prestige Brands Holdings Inc is engaged in the marketing, sales and distribution of well-recognized, brand name OTC healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-18 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+3.76 (+2.05%)

USD 83.17B
TAK Takeda Pharmaceutical Co Ltd A..

+0.06 (+0.40%)

USD 47.69B
HLN Haleon plc

+0.13 (+1.28%)

USD 46.39B
RDY Dr. Reddy’s Laboratories Ltd..

+0.63 (+0.78%)

USD 13.90B
CTLT Catalent Inc

+0.02 (+0.03%)

USD 11.03B
ELAN Elanco Animal Health

-0.12 (-0.79%)

USD 7.56B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 2.63B
BHC Bausch Health Companies Inc

+0.16 (+2.64%)

USD 2.29B
PAHC Phibro Animal Health Corporati..

-0.22 (-1.11%)

USD 0.85B
BIOYF Biosyent Inc.

N/A

USD 0.10B

ETFs Containing PBH

BGC:CA Bristol Gate Concentrated.. 4.73 % 0.84 %

N/A

CAD 0.02B
XST:CA iShares S&P/TSX Capped Co.. 3.15 % 0.61 %

+0.09 (+0.72%)

CAD 0.23B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.06 (0.72%)

USD 0.20B
NDIA Global X Funds 0.00 % 0.00 %

+0.23 (+0.72%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.91% 73% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.91% 73% C 80% B-
Trailing 12 Months  
Capital Gain 17.14% 67% D+ 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.14% 67% D+ 71% C-
Trailing 5 Years  
Capital Gain 123.03% 100% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 123.03% 100% F 89% A-
Average Annual (5 Year Horizon)  
Capital Gain 15.94% 88% B+ 80% B-
Dividend Return 15.94% 88% B+ 78% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.21% 81% B- 49% F
Risk Adjusted Return 75.14% 100% F 90% A-
Market Capitalization 2.60B 50% F 71% C-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.00 87% 51%
Price/Book Ratio 2.11 44% 41%
Price / Cash Flow Ratio 14.04 40% 28%
Price/Free Cash Flow Ratio 12.25 44% 33%
Management Effectiveness  
Return on Equity 13.50% 88% 69%
Return on Invested Capital 9.89% 87% 65%
Return on Assets 6.42% 88% 81%
Debt to Equity Ratio 68.02% 54% 49%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector